149 related articles for article (PubMed ID: 35145039)
1. Medical treatments for idiopathic pulmonary fibrosis: a systematic review and network meta-analysis.
Pitre T; Mah J; Helmeczi W; Khalid MF; Cui S; Zhang M; Husnudinov R; Su J; Banfield L; Guy B; Coyne J; Scallan C; Kolb MR; Jones A; Zeraatkar D
Thorax; 2022 Dec; 77(12):1243-1250. PubMed ID: 35145039
[TBL] [Abstract][Full Text] [Related]
2. Treatment of idiopathic pulmonary fibrosis: a network meta-analysis.
Rochwerg B; Neupane B; Zhang Y; Garcia CC; Raghu G; Richeldi L; Brozek J; Beyene J; Schünemann H
BMC Med; 2016 Feb; 14():18. PubMed ID: 26843176
[TBL] [Abstract][Full Text] [Related]
3. Sildenafil for idiopathic pulmonary fibrosis: A systematic review and meta-analysis.
Pitre T; Khalid MF; Cui S; Zhang MC; Husnudinov R; Mah J; Helmczi W; Su J; Guy B; Scallan C; Jones A; Zeraatkar D
Pulm Pharmacol Ther; 2022 Jun; 73-74():102128. PubMed ID: 35452834
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive comparison of the safety and efficacy of drugs in the treatment of idiopathic pulmonary fibrosis: a network meta-analysis based on randomized controlled trials.
Wu X; Li W; Luo Z; Chen Y
BMC Pulm Med; 2024 Jan; 24(1):58. PubMed ID: 38281037
[TBL] [Abstract][Full Text] [Related]
5. Systematic Review and Meta-analysis of Pirfenidone, Nintedanib, and Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis.
Di Martino E; Provenzani A; Vitulo P; Polidori P
Ann Pharmacother; 2021 Jun; 55(6):723-731. PubMed ID: 33054319
[TBL] [Abstract][Full Text] [Related]
6. Drug Treatment of Idiopathic Pulmonary Fibrosis: Systematic Review and Network Meta-Analysis.
Canestaro WJ; Forrester SH; Raghu G; Ho L; Devine BE
Chest; 2016 Mar; 149(3):756-66. PubMed ID: 26836914
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial.
Behr J; Nathan SD; Wuyts WA; Mogulkoc Bishop N; Bouros DE; Antoniou K; Guiot J; Kramer MR; Kirchgaessler KU; Bengus M; Gilberg F; Perjesi A; Harari S; Wells AU
Lancet Respir Med; 2021 Jan; 9(1):85-95. PubMed ID: 32822614
[TBL] [Abstract][Full Text] [Related]
8. Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis.
Rogliani P; Calzetta L; Cavalli F; Matera MG; Cazzola M
Pulm Pharmacol Ther; 2016 Oct; 40():95-103. PubMed ID: 27481628
[TBL] [Abstract][Full Text] [Related]
9. A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK.
Rinciog C; Watkins M; Chang S; Maher TM; LeReun C; Esser D; Diamantopoulos A
Pharmacoeconomics; 2017 Apr; 35(4):479-491. PubMed ID: 28039616
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of N-acetylcysteine plus pirfenidone in the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis.
Zhang XL; Cao Y; Zheng B
BMC Pulm Med; 2023 Nov; 23(1):479. PubMed ID: 38031002
[TBL] [Abstract][Full Text] [Related]
11. The clinical effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: a systematic review and economic evaluation.
Loveman E; Copley VR; Colquitt J; Scott DA; Clegg A; Jones J; O'Reilly KM; Singh S; Bausewein C; Wells A
Health Technol Assess; 2015 Mar; 19(20):i-xxiv, 1-336. PubMed ID: 25760991
[TBL] [Abstract][Full Text] [Related]
12. Systematic review and network meta-analysis of approved medicines for the treatment of idiopathic pulmonary fibrosis.
Skandamis A; Kani C; Markantonis SL; Souliotis K
J Drug Assess; 2019; 8(1):55-61. PubMed ID: 31044096
[No Abstract] [Full Text] [Related]
13. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis.
Finnerty JP; Ponnuswamy A; Dutta P; Abdelaziz A; Kamil H
BMC Pulm Med; 2021 Dec; 21(1):411. PubMed ID: 34895203
[TBL] [Abstract][Full Text] [Related]
14. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
Behr J; Bendstrup E; Crestani B; Günther A; Olschewski H; Sköld CM; Wells A; Wuyts W; Koschel D; Kreuter M; Wallaert B; Lin CY; Beck J; Albera C
Lancet Respir Med; 2016 Jun; 4(6):445-53. PubMed ID: 27161257
[TBL] [Abstract][Full Text] [Related]
15. The effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: systematic review, network meta-analysis and health economic evaluation.
Loveman E; Copley VR; Colquitt JL; Scott DA; Clegg AJ; Jones J; O'Reilly KM; Singh S; Bausewein C; Wells A
BMC Pharmacol Toxicol; 2014 Nov; 15():63. PubMed ID: 25410822
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and adverse events of pirfenidone in treating idiopathic pulmonary fibrosis.
Ren H; Wang K; Yang H; Gao L
Saudi Med J; 2017 Sep; 38(9):889-894. PubMed ID: 28889145
[TBL] [Abstract][Full Text] [Related]
17. Sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: A Phase IIb, randomised, double-blind, placebo-controlled study - Rationale and study design.
Behr J; Nathan SD; Harari S; Wuyts W; Kirchgaessler KU; Bengus M; Gilberg F; Wells AU
Respir Med; 2018 May; 138():13-20. PubMed ID: 29724385
[TBL] [Abstract][Full Text] [Related]
18. N-acetylcysteine for non-paracetamol (acetaminophen)-related acute liver failure.
Siu JT; Nguyen T; Turgeon RD
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD012123. PubMed ID: 33294991
[TBL] [Abstract][Full Text] [Related]
19. Comparing new treatments for idiopathic pulmonary fibrosis--a network meta-analysis.
Loveman E; Copley VR; Scott DA; Colquitt JL; Clegg AJ; O'Reilly KM
BMC Pulm Med; 2015 Apr; 15():37. PubMed ID: 25927225
[TBL] [Abstract][Full Text] [Related]
20. Impact of Antifibrotic Therapy on Mortality and Acute Exacerbation in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.
Petnak T; Lertjitbanjong P; Thongprayoon C; Moua T
Chest; 2021 Nov; 160(5):1751-1763. PubMed ID: 34217681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
